可逆病因心脏骤停幸存者的复发性室性心律失常与死亡率:植入型心律转复除颤器与非植入型心律转复除颤器的系统评价
该系统评价纳入27项研究、11,402例可逆病因心脏骤停幸存者,其中2,570例植入ICD,按病因分为急性心肌梗死、冠状动脉痉挛、Takotsubo心肌病及多种可逆病因四组,评估ICD植入对死亡率和恰当装置治疗的影响。冠状动脉痉挛组和多种可逆病因组的恰当装置治疗率较高(分别为17%和20%),并报告ICD患者生存率提高;Takotsubo心肌病组死亡率低,且无ICD患者接受恰当装置治疗;急性心肌梗死组结果不一致,恰当装置治疗率高(12-66%),但植入与未植入ICD患者的死亡率结果不一。结论认为可逆病因心脏骤停幸存者的室性心律失常复发风险因病因不同而异,不应作为同一整体评估,部分患者可能从ICD植入中获益。
要点
- 该系统评价纳入27项研究、11,402例可逆病因心脏骤停幸存者,其中2,570例植入ICD。
- 冠状动脉痉挛组和多种可逆病因组的恰当装置治疗率分别为17%和20%,并报告ICD患者生存率提高。
- Takotsubo心肌病组死亡率低,且无ICD患者接受恰当装置治疗。
- 急性心肌梗死组结果不一致,恰当装置治疗率高(12-66%),但植入与未植入ICD患者的死亡率结果不一。
- 作者认为可逆病因心脏骤停幸存者的室性心律失常复发风险因病因不同而异,不应作为同一整体评估,部分患者可能从ICD植入中获益。
适用人群与场景
- 可逆病因心脏骤停幸存者,按病因分为急性心肌梗死、冠状动脉痉挛、Takotsubo心肌病及多种可逆病因四组。
研究设计与关键结果
- 系统评价纳入27项研究,评估11,402例可逆病因心脏骤停幸存者,其中2,570例植入ICD。
- 冠状动脉痉挛组和多种可逆病因组的恰当装置治疗率分别为17%和20%,并报告ICD患者生存率提高。
- Takotsubo心肌病组死亡率低,且无ICD患者接受恰当装置治疗。
- 急性心肌梗死组结果不一致,恰当装置治疗率高(12-66%),但植入与未植入ICD患者的死亡率结果不一。
- 作者结论认为可逆病因心脏骤停幸存者的室性心律失常复发风险因病因不同而异,不应作为同一整体评估,部分患者可能从ICD植入中获益。
证据类型、等级与局限
- 证据类型:系统评价。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为可逆病因心脏骤停幸存者的室性心律失常复发风险因病因不同而异,不应作为同一整体评估,部分患者可能从ICD植入中获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sudden cardiac arrest survivors with a reversible cause are not eligible for implantable cardioverter defibrillator (ICD) implantation. This study aims to evaluate the risk of recurrent ventricular arrhythmia in sudden cardiac arrest survivors with a reversible cause and evaluate if ICD implantation increases survival.
METHODS: We conducted a systematic review to identify studies evaluating ICD implantation in sudden cardiac arrest survivors with a reversible cause. Outcomes were mortality and appropriate device therapy. Sudden cardiac arrest patients were divided into 4 subgroups: due to acute myocardial infarction; due to coronary artery spasm; due to takotsubo cardiomyopathy; and studies with various reversible causes of cardiac arrest.
RESULTS: 27 studies were included, evaluating 11,402 patients. A total of 2570 patients received an ICD. Studies evaluating coronary artery spasm and with various reversible causes showed a relatively high rate of appropriate device therapy (17% and 20%) and described an increased survival in ICD patients. Takotsubo cardiomyopathy was associated with a low mortality and none of the ICD patients received appropriate device therapy. Studies evaluating acute myocardial infarction survivors reported inconsistent results, with high numbers of appropriate device therapy (12-66%), but the mortality-rate of patients with and without an ICD varied.
CONCLUSION: This study shows that the recurrence risk of ventricular arrhythmia varies between different reversible causes of sudden cardiac arrest and should not be evaluated as one entity. Cardiac arrest survivors with a reversible cause can be at risk of recurrent ventricular arrhythmia and selected patients may benefit from ICD implantation.
参考来源
- van der Lingen ACJ, Woudstra J, Becker MAJ, et al. Recurrent ventricular arrhythmias and mortality in cardiac arrest survivors with a reversible cause with and without an implantable cardioverter defibrillator: A systematic review. Resuscitation. 2022. PMID: 35227821. doi:10.1016/j.resuscitation.2022.02.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。